J30-8

Cat. No.: HY-125838

CAS No.: 2366255-71-0

Molecular Formula: $C_{17}H_9ClFN_3O_2S$

Molecular Weight: 373.79

Target: JNK

Pathway: MAPK/ERK Pathway

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.67 mg/mL (17.84 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6753 mL	13.3765 mL	26.7530 mL
	5 mM	0.5351 mL	2.6753 mL	5.3506 mL
	10 mM	0.2675 mL	1.3376 mL	2.6753 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 0.67 mg/mL (1.79 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC_{50} of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases[1].

IC_{50} & Target

JNK3
40 nM (IC_{50})

REFERENCES

[1]. Dou X, et al. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J Med Chem. 2019 Jul 25;62(14):6645-6664.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA